Product introduction
Pegstim Injection is used to prevent infections after chemotherapy. It is a growth factor that stimulates bone marrow to produce white blood cells. These cells protect the body against infections.
Pegstim Injection is given as an injection by a qualified medical professional. You should continue to take as long as your doctor advises for it. The duration of treatment varies according to your need and response to treatment. You might be asked for regular tests done to check the number of blood cells in your blood and your bone density level while you are taking this medicine.
The most common side effects of this medicine include bone pain, joint pain, headache, nausea, and muscle pain. Other than this, pain or redness at the site of injection is common. But, inform your doctor if you notice a lump, swelling, or bruising that does not go away. It might not prevent you from all kinds of infection, hence inform your doctor if you notice fever, chills, shortness of breath, sore throat, and swelling around the face or neck.
Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy. You must avoid driving or attention-seeking activity if you experience dizziness after taking this medicine.
Uses of Pegstim Injection
- Prevention of Infections after chemotherapy
Benefits of Pegstim Injection
In Prevention of Infections after chemotherapy
Side effects of Pegstim Injection
Common side effects of Pegstim
- Bone pain
- Joint pain
- Headache
- Nausea
- Low blood platelets
- Muscle pain
- Back pain
- Pain in extremities
- Injection site pain
How to use Pegstim Injection
How Pegstim Injection works
Safety advice
Alcohol
Pregnancy
Breast feeding
Driving
Kidney
Liver
What if you forget to take Pegstim Injection?
FAQs
What is Pegstim Injection? How is it given?
How does pegfilgrastim work?
References:-
European Medicines Agency (EMA) – Biosimilar Pegfilgrastim Products
-
Pelmeg (Mundipharma)
A pegfilgrastim biosimilar (6 mg pre-filled syringe) authorised for reducing neutropenia duration post-chemotherapy.
https://www.ema.europa.eu/en/medicines/human/EPAR/pelmeg European Medicines Agency (EMA) -
Pelgraz (Accord Healthcare)
Another EU biosimilar, approved for the same indication and similar in structure to the reference product Neulasta.
https://www.ema.europa.eu/en/medicines/human/EPAR/pelgraz European Medicines Agency (EMA) -
Cegfila (Mundipharma’s pegfilgrastim)
EU-approved biosimilar comparable in efficacy and safety to Neulasta, supplied as a 6 mg pre-filled injection.
https://www.ema.europa.eu/en/medicines/human/EPAR/cegfila European Medicines Agency (EMA) -
Vivlipeg (Positive CHMP opinion June 2025)
A newer pegfilgrastim biosimilar recommended for approval in the EU, also intended for the same neutropenia indication.
https://www.ema.europa.eu/en/medicines/human/EPAR/vivlipeg European Medicines Agency (EMA)
Clinical & Medical Overviews
-
Wikipedia – Pegfilgrastim Overview
Offers background on pegfilgrastim’s mechanism, approval timeline, and inclusion in the WHO Essential Medicines List.
https://en.wikipedia.org/wiki/Pegfilgrastim
Reviews
There are no reviews yet.